MiMedx Group (NASDAQ:MDXG) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of MiMedx Group (NASDAQ:MDXG) in a research report report published on Wednesday, Benzinga reports. They currently have a $11.00 price target on the stock. HC Wainwright also issued estimates for MiMedx Group’s Q4 2024 earnings at $0.11 EPS.

A number of other equities analysts have also recently commented on the company. Mizuho lifted their price target on MiMedx Group from $13.00 to $14.00 and gave the stock a buy rating in a research note on Friday, March 1st. Lake Street Capital initiated coverage on shares of MiMedx Group in a report on Thursday, March 7th. They set a buy rating and a $12.00 price target for the company. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of Buy and an average price target of $12.25.

MiMedx Group Stock Up 18.7 %

Shares of NASDAQ MDXG opened at $7.31 on Wednesday. The stock has a market capitalization of $1.08 billion, a P/E ratio of 16.61 and a beta of 1.44. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.57 and a quick ratio of 3.11. MiMedx Group has a one year low of $3.79 and a one year high of $9.27. The firm’s 50 day simple moving average is $7.39 and its two-hundred day simple moving average is $7.56.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings results on Wednesday, February 28th. The company reported $0.04 earnings per share for the quarter, missing the consensus estimate of $0.08 by ($0.04). MiMedx Group had a return on equity of 64.61% and a net margin of 18.63%. The business had revenue of $86.83 million during the quarter, compared to the consensus estimate of $85.58 million. As a group, analysts expect that MiMedx Group will post 0.33 EPS for the current fiscal year.

Insider Buying and Selling

In other MiMedx Group news, COO Ricci S. Whitlow sold 15,271 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $8.01, for a total transaction of $122,320.71. Following the transaction, the chief operating officer now directly owns 401,050 shares of the company’s stock, valued at approximately $3,212,410.50. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other MiMedx Group news, COO Ricci S. Whitlow sold 15,271 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The shares were sold at an average price of $8.01, for a total value of $122,320.71. Following the completion of the sale, the chief operating officer now directly owns 401,050 shares in the company, valued at $3,212,410.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Ricci S. Whitlow sold 15,493 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $8.07, for a total value of $125,028.51. Following the completion of the transaction, the chief operating officer now directly owns 416,321 shares of the company’s stock, valued at approximately $3,359,710.47. The disclosure for this sale can be found here. Insiders sold 51,145 shares of company stock valued at $409,378 over the last quarter. 19.90% of the stock is owned by company insiders.

Hedge Funds Weigh In On MiMedx Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. AJOVista LLC bought a new position in shares of MiMedx Group in the 4th quarter worth about $25,000. DekaBank Deutsche Girozentrale purchased a new stake in shares of MiMedx Group in the third quarter worth $38,000. Robeco Institutional Asset Management B.V. bought a new position in shares of MiMedx Group during the third quarter valued at $74,000. M&T Bank Corp bought a new position in shares of MiMedx Group during the third quarter valued at $75,000. Finally, E Fund Management Co. Ltd. purchased a new position in shares of MiMedx Group in the 3rd quarter worth about $84,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.